New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 Inhibitors
AstraZeneca has announced results from a new analysis of its landmark CVD-REAL study, the first large real-world evidence study of its kind evaluating the risk of all-cause death (ACD), hospitalisation for heart failure (hHF), heart attack (myocardial infarction or MI) and stroke in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i), including Farxiga (dapagliflozin) versus other glucose-lowering medicines.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
More News: AstraZeneca | Cardiology | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Heart | Heart Attack | Heart Failure | Pharmaceuticals | Stroke | Study